- Regulatory Affairs: the case may now shift from defending the original cardiomyopathy indication to aligning the filing with the strongest efficacy evidence.
- Clinical and biostatistics teams: the dispute places endpoint selection and statistical analysis under renewed scrutiny.
- Quality teams: the case highlights the importance of keeping clinical reports, analysis plans and regulatory submissions consistent and traceable.
FDA Panel Rejected Deramiocel, Now Capricor Is Taking a Different Regulatory Path
On July 29, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee reviewed BLA 125842 for deramiocel. The panel voted three in favor and nine against whether the available evidence provided substantial evidence of effectiveness for treating cardiomyopathy in patients with DMD. However, the committee did not vote on the HOPE-3 primary endpoint or the therapy’s overall benefit-risk profile.
HOPE-3 enrolled 106 males with DMD and used upper-limb function measured by PUL 2.0 as its prespecified primary endpoint. Capricor reported a statistically significant result at p=0.029. Meanwhile, cardiac function served as a key secondary endpoint, although the proposed indication focused on cardiomyopathy.
The evidence package became more complicated during peer review of the HOPE-3 results in The Lancet. Capricor said it identified an issue in the statistical model used in the clinical study report and returned to the statistical analysis plan in place before unblinding. Consequently, the LVEF analysis changed from p=0.04 to p=0.09. However, the company said the primary endpoint remained unchanged.
Capricor’s Next Move Could Reshape the FDA Decision on Deramiocel
CEO Linda Marbán said Capricor now plans to submit a BLA amendment containing 24-month open-label extension data from HOPE-3 and additional analyses from the existing evidence package. The company intends to use the amendment to support a refined indication centered on the trial’s primary endpoint.
Marbán also said the FDA had indicated that it was willing to review the amendment and extend the PDUFA action date after receiving it. However, BioSpace and Reuters reported that the FDA or its parent department had not independently confirmed that position at publication.
The regulatory uncertainty has already affected Capricor beyond the BLA. The company has slowed commercial readiness and placed programs unrelated to deramiocel, including its exosome-based platform, on hold while it waits for greater regulatory clarity.
The table below summarizes the key regulatory risks, actions, evidence, and timelines arising from the deramiocel review.
| Role | Main risk | Immediate action | Evidence needed | Timing |
|---|---|---|---|---|
|
Regulatory Affairs |
Indication and evidence misalignment |
Reassess filing strategy |
Endpoint-to-indication rationale |
Before amendment submission |
|
Clinical/Biostatistics |
Statistical analysis challenged |
Reconcile SAP and CSR |
Controlled analysis records |
Before the next FDA interaction |
|
QA |
Evidence traceability gaps |
Verify change history |
Approved review records |
Before dossier update |
|
Leadership |
Regulatory delay affects investment decisions |
Reassess resource allocation |
Updated regulatory scenario |
After revised PDUFA timing |
The next milestones will determine whether this strategy changes deramiocel’s regulatory path. Capricor must first finalize the amendment. Then, the FDA would need to establish a revised action date and ultimately decide whether the new data and refined indication support a different outcome.
For regulatory professionals, the decision is practical: if a pivotal study meets its primary endpoint but the proposed indication depends heavily on a disputed secondary endpoint, would you defend the original indication or narrow the filing around the strongest evidence?
What Pharma Teams Can Learn From Capricor’s FDA Setback
Zamann Pharma Support’s Quality Management System service helps pharmaceutical teams strengthen controlled documentation, change management and compliance processes when regulatory evidence evolves across the product lifecycle. If your team needs a more structured framework for managing regulatory changes while keeping quality records consistent and inspection-ready, explore Zamann Pharma’s QMS support.
Source: Biospace.Com